Ashutosh Dash1, Maroor Raghavan Ambikalmajan Pillai2, Furn F Knapp3. 1. Isotope Production and Applications Division, Bhabha Atomic Research Centre (BARC), Trombay, Mumbai 400 085 India. 2. Molecular Group of Companies, Kochi, 780001 Kerala India. 3. Medical Isotopes Program, Isotope Development Group, Oak Ridge National Laboratory (ORNL), P.O. Box 2008, MS 6229, Bldg, 4501, 1 Bethel Valley Road,, Oak Ridge, TN 37831-6229 USA.
Abstract
BACKGROUND: This review provides a comprehensive summary of the production of (177)Lu to meet expected future research and clinical demands. Availability of options represents the cornerstone for sustainable growth for the routine production of adequate activity levels of (177)Lu having the required quality for preparation of a variety of (177)Lu-labeled radiopharmaceuticals. The tremendous prospects associated with production of (177)Lu for use in targeted radionuclide therapy (TRT) dictate that a holistic consideration should evaluate all governing factors that determine its success. METHODS: While both "direct" and "indirect" reactor production routes offer the possibility for sustainable (177)Lu availability, there are several issues and challenges that must be considered to realize the full potential of these production strategies. RESULTS: This article presents a mini review on the latest developments, current status, key challenges and possibilities for the near future. CONCLUSION: A broad understanding and discussion of the issues associated with (177)Lu production and processing approaches would not only ensure sustained growth and future expansion for the availability and use of (177)Lu-labeled radiopharmaceuticals, but also help future developments.
BACKGROUND: This review provides a comprehensive summary of the production of (177)Lu to meet expected future research and clinical demands. Availability of options represents the cornerstone for sustainable growth for the routine production of adequate activity levels of (177)Lu having the required quality for preparation of a variety of (177)Lu-labeled radiopharmaceuticals. The tremendous prospects associated with production of (177)Lu for use in targeted radionuclide therapy (TRT) dictate that a holistic consideration should evaluate all governing factors that determine its success. METHODS: While both "direct" and "indirect" reactor production routes offer the possibility for sustainable (177)Lu availability, there are several issues and challenges that must be considered to realize the full potential of these production strategies. RESULTS: This article presents a mini review on the latest developments, current status, key challenges and possibilities for the near future. CONCLUSION: A broad understanding and discussion of the issues associated with (177)Lu production and processing approaches would not only ensure sustained growth and future expansion for the availability and use of (177)Lu-labeled radiopharmaceuticals, but also help future developments.
Authors: Christina Swärd; Peter Bernhardt; Viktor Johanson; Anneli Schmitt; Håkan Ahlman; Mats Stridsberg; Eva Forssell-Aronsson; Ola Nilsson; Lars Kölby Journal: Cancer Biother Radiopharm Date: 2008-02 Impact factor: 3.099
Authors: Sudipta Chakraborty; K V Vimalnath; A Rajeswari; Ajit Shinto; H D Sarma; K Kamaleshwaran; P Thirumalaisamy; Ashutosh Dash Journal: J Labelled Comp Radiopharm Date: 2014-06-15 Impact factor: 1.921
Authors: Wouter A P Breeman; Amir Mearadji; Astrid Capello; Bert F Bernard; Casper H J van Eijck; Eric P Krenning; Marion de Jong Journal: Int J Cancer Date: 2003-04-10 Impact factor: 7.396
Authors: B L R Kam; J J M Teunissen; E P Krenning; W W de Herder; S Khan; E I van Vliet; D J Kwekkeboom Journal: Eur J Nucl Med Mol Imaging Date: 2012-02 Impact factor: 9.236
Authors: Xiaoxi Ling; Joseph D Latoche; Cindy J Choy; Brenda F Kurland; Charles M Laymon; Yijen Wu; Nathan Salamacha; Ding Shen; Jonathan J Geruntho; Lora H Rigatti; Hillarie P Windish; Beatrice Langton-Webster; Clifford E Berkman; Carolyn J Anderson Journal: Mol Imaging Biol Date: 2020-04 Impact factor: 3.488
Authors: Bo Yu; Hao Wei; Qianjun He; Carolina A Ferreira; Christopher J Kutyreff; Dalong Ni; Zachary T Rosenkrans; Liang Cheng; Faquan Yu; Jonathan W Engle; Xiaoli Lan; Weibo Cai Journal: Angew Chem Int Ed Engl Date: 2017-11-30 Impact factor: 15.336
Authors: Philipp Backhaus; Benjamin Noto; Nemanja Avramovic; Lena Sophie Grubert; Sebastian Huss; Martin Bögemann; Lars Stegger; Matthias Weckesser; Michael Schäfers; Kambiz Rahbar Journal: Eur J Nucl Med Mol Imaging Date: 2018-01-15 Impact factor: 9.236